medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2007, Number 5

<< Back Next >>

Rev Mex Urol 2007; 67 (5)

Cut point of the fraction free from prostatic specific antigen in Mexican population susceptible to prostate cancer

Martínez AC, Salgueiro ER, Paredes MJ, Marina GJM, Pacheco GC, Calderón FF, Mata MMP

Language: Spanish
References: 22
Page: 248-255
PDF size: 609.35 Kb.


ABSTRACT

Background: The percent free prostatic specific antigen was associated with prostate cancer, a lowest percentage in the relationship had a more probabi-lity to appear cancer, and this coefficent is most specific and sensibility between 4 to 10 ng/mL.
Objective: Identifying and learning about the cutting point of the fraction free in gray area, rectal tact, age at Mexican population and compare it with the world.
Methods: It’s a retrolective, biinstitutional, transverse, descriptive and comparative, observational open study design, from August 1999 to October 2004, included 331 patients with age, rectal examination, total prostate specific antigen (4-10 ng/mL) free prostatic specific antigen, percentage free antigen and transrectal biopsy.
Results: Our global correlation with percentage free/total prostatic specific antigen, rectal examination and age, results a cut-offs in 12%, when compared rectal examination with age, this va-lues was 12.6 and 12 % from normal digital rectal examination, in the abnormal examination the values was 12 and 13% for patients with less and more 70 years, respectively.
Conclusion: The real value in the relation free/total prostate specific antigen was 12%, with this, had more prostate cancer detection with a great sensibility and had less false-positive to 35%.


REFERENCES

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:144.

  2. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project: findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-58.

  3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23.

  4. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-16.

  5. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1987;145:984.

  6. McCormack RT, Rittenhouse HG, Finlay JA et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family, Urology. 1995;45:729-44.

  7. Christensson A, Laurell CB, Lilja H. Enzimatic activity of the prostate-specific antigen and its reactions with extracelular serine proteinase inhibitors. Eur J Biochem. 1990;194:755-763.

  8. Stenman UH, Leinonen J, Alfthan H et al. A complex between prostate-specific antigen and alpha-1 antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-6.

  9. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-20.

  10. Del Valle GL, Solares SM, Maldonado VR et al. Experiencia del Servicio de Urología del Hospital General Manuel Gea González en el uso de la fracción libre del Antígeno Prostático en la detección del Cáncer de Próstata Localizado. Rev Mex Urol. 2002;62(4):172-5.

  11. Catalona WJ, Partin AW, Slawin KM et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology. 2000;55:372-6.

  12. Christensson A, Björk T, Nilsson O et al. Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-5.

  13. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76:1899-903.

  14. Catalona WJ, Hudson MA, Scardino PT et al. Selection of optimal prostate specific antigen cutoffs of early detection of prostate cancer. Receiver operating characteristic curves. J Urol. 1994;152:2037-42.

  15. Lilja H, Christensson A, Dahlén U et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 1991;37:1618-25.

  16. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin of North Am. 1997;24(2):353-65.

  17. Luderer AA, Chen YT, Soriano TF et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology. 1995;46:187-94.

  18. Arcangeli GC, Ornstein KD, Keetch WD, Andriole LG. Prostate-specific antigen as a screening test for prostate cancer. The United States Experience. Urol Clin of North Am. 1997;24(2):299.

  19. Vashi AR, Wojno KJ, Vessella RL et al. Determination of the “reflex range” and appropriate cut points for percent free-PSA in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 1997; 49(1): 19-27.

  20. Reissigli A, Bartsch G. Prostate-specific antigen as a screening test. The Austrian Experience. Urol Clin of North Am. 1997;24(2):315.

  21. Bangma CH, Kranse R, Blijenberg B et al. The value of screening test in the detection of prostate cancer: A simulation of the role of the F/T ratio, age specific reference ranges, and PSA density. Urology. 1995; 46(6): 779-84.

  22. Bangma CH, Rietbergen BWJ, Schröder HF. Prostate-specific antigen as a screening test. The Netherlands Experience. Urol Clin of North Am. 1997;24(2):307.




2020     |     www.medigraphic.com